Immunohistochemical expression of PRAME in 485 cases of
epithelial tubo-ovarian tumors

J 2023

Immunohistochemical expression of PRAME in 485 cases of epithelial tubo-ovarian tumors

SAFANDA, Adam, Michaela KENDALL BARTU, Romana MICHALKOVA, Ivana STRUZINSKA, Jana DROZENOVA et. al.

Základní údaje

Originální název

Immunohistochemical expression of PRAME in 485 cases of epithelial tubo-ovarian tumors

Autoři

SAFANDA, Adam (203 Česká republika), Michaela KENDALL BARTU (203 Česká republika), Romana MICHALKOVA (203 Česká republika), Ivana STRUZINSKA (203 Česká republika), Jana DROZENOVA (203 Česká republika), Pavel FABIAN (203 Česká republika), Jitka HAUSNEROVÁ (203 Česká republika, domácí), Jan LACO (203 Česká republika), Radoslav MATEJ (203 Česká republika), Petr SKAPA (203 Česká republika), Marian SVAJDLER (203 Česká republika), Zuzana SPURKOVA (203 Česká republika), Gabor MEHES (203 Česká republika), Pavel DUNDR (203 Česká republika) a Kristyna NEMEJCOVA (203 Česká republika)

Vydání

Virchows Archiv, New York, Springer, 2023, 0945-6317

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30109 Pathology

Stát vydavatele

Spojené státy

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 3.500 v roce 2022

Kód RIV

RIV/00216224:14110/23:00133230

Organizační jednotka

Lékařská fakulta

DOI

http://dx.doi.org/10.1007/s00428-023-03629-z

UT WoS

001063398000003

Klíčová slova anglicky

PRAME; Immunohistochemistry; Ovarian tumors; Cancer

Štítky

14110230, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 25. 1. 2024 15:19, Mgr. Tereza Miškechová

Anotace

V originále

Preferentially expressed antigen of melanoma (PRAME) is a cancer/testis antigen selectively expressed in somatic tissues and various solid malignant tumors and is associated with poor prognostic outcome. Our research aimed to comprehensively compare its expression in a large cohort of tubo-ovarian epithelial tumors and examine its correlation with our clinico-pathologic data, as well as to assess its potential use in diagnostics and therapy.We examined 485 cases of epithelial tubo-ovarian tumors including 107 clear cell carcinomas (CCC), 52 endometroid carcinomas (EC), 103 high grade serous carcinomas (HGSC), 119 low grade serous carcinomas (LGSC)/micropapillary variant of serous borderline tumors (mSBT), and 104 cases of mucinous carcinomas (MC)/mucinous borderline tumors (MBT). The immunohistochemical analysis was performed using TMAs.The highest levels of expression were seen in EC (60%), HGSC (62%), and CCC (56%), while expression in LGSC/mSBT (4%) and MC/MBT (2%) was rare. The clinico-pathologic correlations and survival analysis showed no prognostic significance.The results of our study showed that PRAME is neither prognostic nor a suitable ancillary marker in the differential diagnosis of tubo-ovarian epithelial tumors. Nevertheless, knowledge about the PRAME expression may be important concerning its potential predictive significance, because targeting PRAME as a potential therapeutic option is currently under investigation.

Návaznosti

90233, velká výzkumná infrastruktura

Název: BBMRI.cz IV

Citovat

SAFANDA, Adam, Michaela KENDALL BARTU, Romana MICHALKOVA, Ivana STRUZINSKA, Jana DROZENOVA, Pavel FABIAN, Jitka HAUSNEROVÁ, Jan LACO, Radoslav MATEJ, Petr SKAPA, Marian SVAJDLER, Zuzana SPURKOVA, Gabor MEHES, Pavel DUNDR a Kristyna NEMEJCOVA. Immunohistochemical expression of PRAME in 485 cases of epithelial tubo-ovarian tumors. Virchows Archiv. New York: Springer, 2023, roč. 483, č. 4, s. 509-516. ISSN 0945-6317. Dostupné z: https://dx.doi.org/10.1007/s00428-023-03629-z.

@article{2365649,
   author = {Safanda, Adam and Kendall Bartu, Michaela and Michalkova, Romana and Struzinska, Ivana and Drozenova, Jana and Fabian, Pavel and Hausnerová, Jitka and Laco, Jan and Matej, Radoslav and Skapa, Petr and Svajdler, Marian and Spurkova, Zuzana and Mehes, Gabor and Dundr, Pavel and Nemejcova, Kristyna},
   article_location = {New York},
   article_number = {4},
   doi = {http://dx.doi.org/10.1007/s00428-023-03629-z},
   keywords = {PRAME; Immunohistochemistry; Ovarian tumors; Cancer},
   language = {eng},
   issn = {0945-6317},
   journal = {Virchows Archiv},
   title = {Immunohistochemical expression of PRAME in 485 cases of epithelial tubo-ovarian tumors},
   url = {https://link.springer.com/article/10.1007/s00428-023-03629-z},
   volume = {483},
   year = {2023}
}

TY  - JOUR
ID  - 2365649
AU  - Safanda, Adam - Kendall Bartu, Michaela - Michalkova, Romana - Struzinska, Ivana - Drozenova, Jana - Fabian, Pavel - Hausnerová, Jitka - Laco, Jan - Matej, Radoslav - Skapa, Petr - Svajdler, Marian - Spurkova, Zuzana - Mehes, Gabor - Dundr, Pavel - Nemejcova, Kristyna
PY  - 2023
TI  - Immunohistochemical expression of PRAME in 485 cases of epithelial tubo-ovarian tumors
JF  - Virchows Archiv
VL  - 483
IS  - 4
SP  - 509-516
EP  - 509-516
PB  - Springer
SN  - 09456317
KW  - PRAME
KW  - Immunohistochemistry
KW  - Ovarian tumors
KW  - Cancer
UR  - https://link.springer.com/article/10.1007/s00428-023-03629-z
N2  - Preferentially expressed antigen of melanoma (PRAME) is a cancer/testis antigen selectively expressed in somatic tissues and various solid malignant tumors and is associated with poor prognostic outcome. Our research aimed to comprehensively compare its expression in a large cohort of tubo-ovarian epithelial tumors and examine its correlation with our clinico-pathologic data, as well as to assess its potential use in diagnostics and therapy.We examined 485 cases of epithelial tubo-ovarian tumors including 107 clear cell carcinomas (CCC), 52 endometroid carcinomas (EC), 103 high grade serous carcinomas (HGSC), 119 low grade serous carcinomas (LGSC)/micropapillary variant of serous borderline tumors (mSBT), and 104 cases of mucinous carcinomas (MC)/mucinous borderline tumors (MBT). The immunohistochemical analysis was performed using TMAs.The highest levels of expression were seen in EC (60%), HGSC (62%), and CCC (56%), while expression in LGSC/mSBT (4%) and MC/MBT (2%) was rare. The clinico-pathologic correlations and survival analysis showed no prognostic significance.The results of our study showed that PRAME is neither prognostic nor a suitable ancillary marker in the differential diagnosis of tubo-ovarian epithelial tumors. Nevertheless, knowledge about the PRAME expression may be important concerning its potential predictive significance, because targeting PRAME as a potential therapeutic option is currently under investigation.
ER  -

SAFANDA, Adam, Michaela KENDALL BARTU, Romana MICHALKOVA, Ivana STRUZINSKA, Jana DROZENOVA, Pavel FABIAN, Jitka HAUSNEROVÁ, Jan LACO, Radoslav MATEJ, Petr SKAPA, Marian SVAJDLER, Zuzana SPURKOVA, Gabor MEHES, Pavel DUNDR a Kristyna NEMEJCOVA. Immunohistochemical expression of PRAME in 485 cases of epithelial tubo-ovarian tumors. \textit{Virchows Archiv}. New York: Springer, 2023, roč.~483, č.~4, s.~509-516. ISSN~0945-6317. Dostupné z: https://dx.doi.org/10.1007/s00428-023-03629-z.

Podrobný výpis o publikaci